News | Mammography | January 12, 2021

This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately

This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately

January 12, 2021 — Therapixel announced that MammoScreen has successfully obtained the CE mark. After having received FDA clearance for commercial sales in the United States in March 2020, this artificial intelligence (AI) solution is now available in the European market.

MammoScreen automatically analyzes screening mammograms and indicates suspicious mammograms and lesions to the radiologist. According to the probability of malignancy and the degree of confidence of the algorithm, the software assigns a unique "MammoScreen Score" ranging from 1 to 10.

A clinical study conducted in 2019 and published in Radiology: AI, showed that radiologists assisted by MammoScreen have a better performance than without the software.

MammoScreen helps to increase the interpretation speed of benign images, giving readers more time to focus on cases requiring more attention.

Already installed in 14 hospitals and radiology practices in France for clinical evaluations, MammoScreen has generated a lot of enthusiasm among radiologists. Physicians perceive it as an intuitive and easy-to-use tool that helps reassure themselves in the interpretation and avoid missing cancers.

Breast cancer is one of the most common and deadliest cancers in women worldwide, affecting 1 in 8 women in their lifetime. The earlier this disease is diagnosed, the more effective the treatment is.

"We are proud to have received the CE Mark. This brings us a step closer to our goal of reducing breast cancer burden worldwide by improving breast cancer screening," said Pierre Fillard, Therapixel's Founder and Chief Scientific Officer.

"I am confident that MammoScreen will not only increase radiologists' performance but will also improve the patient experience by reassuring women faster," stated Matthieu Leclerc-Chalvet, CEO of Therapixel.

For more information:

Related Content

News | Breast Density

February 6, 2023 — Awareness of breast density appears to increase one’s perceived breast cancer risk for a short time ...

Time February 06, 2023
News | Radiology Business

February 2, 2023 — Five additional imaging centers across Allegheny Health Network (AHN) have been recognized by the ...

Time February 02, 2023
News | MRI Breast

February 1, 2023 — Compared to other common supplemental screening methods, breast MRI was superior at detecting breast ...

Time February 01, 2023
News | Radiation Therapy

January 31, 2023 — Age-based heuristics can lead to large differences in breast cancer treatment based on small ...

Time January 31, 2023
Webinar | Information Technology

Postpandemic staffing shortages and increased volumes require radiologists to do more with less, exacerbating burnout ...

Time January 30, 2023
News | Stereotactic Breast Imaging

January 27, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), both ...

Time January 27, 2023
News | Artificial Intelligence

January 26, 2023 — MedCognetics, Inc., an Artificial Intelligence (AI) software firm, announced that it has been awarded ...

Time January 26, 2023
News | Artificial Intelligence

Artificial intelligence (AI) is playing a growing role in all our lives and has shown promise in addressing some of the ...

Time January 26, 2023
News | Digital Pathology

January 25, 2023 — mTuitive, Inc. and PathPresenter Corporation announced a new partnership to deliver an enhanced ...

Time January 25, 2023
Feature | Radiology Imaging | By Melinda Taschetta-Millane

Have you read the January/February 2023 issue of Imaging Technology News? If not, take some time out of your busy ...

Time January 24, 2023
Subscribe Now